Tuberous sclerosis complex protein complex (Hamartin–Tuberin complex) (TSC1–TSC2 complex)

The Hamartin–Tuberin complex, also known as the TSC1–TSC2 complex, is a critical intracellular regulator that serves as a primary inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway. Hamartin (TSC1) provides structural stability to the complex, while Tuberin (TSC2) exerts catalytic GTPase-activating protein (GAP) activity toward the small GTPase Rheb. By maintaining Rheb in its inactive GDP-bound state, the complex prevents the activation of mTORC1, thereby controlling essential cellular processes such as protein synthesis, cell growth, and autophagy in response to growth factors and energy levels (Huang & Manning, 2008; UniProt P49815). Mutations in either the TSC1 or TSC2 genes lead to Tuberous Sclerosis Complex (TSC), a genetic disorder characterized by the formation of benign tumors across multiple organ systems, including the brain, kidneys, and lungs. The loss of this complex results in constitutive mTORC1 activation, which drives the pathogenesis of TSC-associated tumors and lymphangioleiomyomatosis (LAM) (Henske et al., 2016). While the complex itself is a tumor suppressor and often lost in disease, it is the focal point for therapeutic strategies using mTOR inhibitors like everolimus and sirolimus, which pharmacologically restore the inhibitory control over the pathway (StatPearls, 2023).

Other names

TSC1–TSC2 complexHamartin–Tuberin complexTSC complexTuberous sclerosis complexRheb GTPase-activating protein complex

The complex acts as a GTPase-activating protein (GAP) for the small GTPase Rheb, converting it from an active GTP-bound state to an inactive GDP-bound state, thereby inhibiting the downstream mTORC1 pathway. Therapeutic agents like mTOR inhibitors bypass the defective complex to directly inhibit the hyperactivated mTORC1 signaling.